Results 11 to 20 of about 583,625 (325)
Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19
Nature Network Boston, 2021 Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are being deployed, but the global need greatly exceeds the supply, and different formulations might be required for specific populations.
B. Ward +18 more
semanticscholar +1 more source
Development of a Virus-Like Particle-Based Anti-HER2 Breast Cancer Vaccine
Cancers, 2021 Simple Summary Virus-like particles (VLPs) have attracted significant interest as immunotherapy platforms and cancer vaccines for inducing antigen-specific immune responses against tumors.
He Hu, N. Steinmetz
semanticscholar +1 more source
Epitope-Specific Anti-hCG Vaccines on a Virus Like Particle Platform. [PDF]
PLoS ONE, 2015 The possibility of a contraceptive vaccine targeting human chorionic gonadotropin has long been recognized, but never fully realized. Here we describe an epitope-specific approach based on immunogenic display of hCG-derived peptides on virus-like ...
Jerri Caldeira +4 more
doaj +1 more source
Vaccines, 2021 SARS-CoV-2 claimed numerous lives and put nations on high alert. The lack of antiviral medications and the small number of approved vaccines, as well as the recurrence of adverse effects, necessitates the development of novel treatment ways to combat ...
Acharya Balkrishna +10 more
semanticscholar +1 more source
Special Issue “Virus-Like Particle Vaccines”
Viruses, 2020 Virus-like particles (VLPs) have become a key tool for vaccine developers and manufacturers [...]
Monique Vogel, Martin F. Bachmann
doaj +1 more source
Vaccines, 2023 New vaccine delivery technologies, such as mRNA, have played a critical role in the rapid and efficient control of SARS-CoV-2, helping to end the COVID-19 pandemic.
Yongping Yang +23 more
doaj +1 more source
Development of Respiratory Syncytial Virus Vaccine Candidates for the Elderly
Viruses, 2023 Respiratory syncytial virus (RSV) is a significant threat to elderly populations and repeated infections that occur throughout life are poorly protective. To assess the role of prior RSV infections as well as elderly immune senescence on vaccine efficacy,
Jorge C. G. Blanco +5 more
doaj +1 more source
Virus-Like Particle-Mediated Vaccination against Interleukin-13 May Harbour General Anti-Allergic Potential beyond Atopic Dermatitis [PDF]
, 2020 Virus-like particle (VLP)-based anti-infective prophylactic vaccination has been established in clinical use. Although validated in proof-of-concept clinical trials in humans, no VLP-based therapeutic vaccination against self-proteins to modulate chronic
Foerster, John, Molęda, Aleksandra
core +2 more sources
Cross-Protection Induced by Virus-like Particles Derived from the Influenza B Virus
Biomedicines, 2022 The mismatch between the circulating influenza B virus (IBV) and the vaccine strain contributes to the rapid emergence of IBV infection cases throughout the globe, which necessitates the development of effective vaccines conferring broad protection. Here,
Hae-Ji Kang +5 more
doaj +1 more source
Journal of the American Medical Association (JAMA), 2020 Importance Chikungunya virus (CHIKV) is a mosquito-borne Alphavirus prevalent worldwide. There are currently no licensed vaccines or therapies. Objective To evaluate the safety and tolerability of an investigational CHIKV virus-like particle (VLP ...
Grace L. Chen +35 more
semanticscholar +1 more source